Emily Luisa Hill Sells 8,938 Shares of Replimune Group, Inc. (NASDAQ:REPL) Stock

Replimune Group, Inc. (NASDAQ:REPL) CFO Emily Luisa Hill sold 8,938 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $10.18, for a total transaction of $90,988.84. Following the transaction, the chief financial officer now directly owns 101,057 shares of the company’s stock, valued at approximately $1,028,760.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Replimune Group Price Performance

NASDAQ:REPL traded up $0.17 on Monday, reaching $10.28. The stock had a trading volume of 687,726 shares, compared to its average volume of 1,190,913. The company has a quick ratio of 10.72, a current ratio of 13.46 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $702.33 million, a P/E ratio of -3.09 and a beta of 1.25. Replimune Group, Inc. has a 1-year low of $4.92 and a 1-year high of $21.32. The stock has a fifty day moving average price of $9.35 and a 200-day moving average price of $7.99.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.10. Research analysts forecast that Replimune Group, Inc. will post -3.15 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on REPL shares. Barclays boosted their price objective on Replimune Group from $13.00 to $17.00 and gave the company an “overweight” rating in a research report on Friday, June 7th. JPMorgan Chase & Co. dropped their price objective on shares of Replimune Group from $17.00 to $14.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th. Wedbush reiterated an “outperform” rating and set a $16.00 target price on shares of Replimune Group in a research report on Thursday, June 6th. Finally, HC Wainwright raised their price target on shares of Replimune Group from $12.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, June 7th.

Institutional Trading of Replimune Group

Several institutional investors and hedge funds have recently made changes to their positions in the business. Tower Research Capital LLC TRC raised its position in shares of Replimune Group by 236.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,207 shares of the company’s stock worth $35,000 after purchasing an additional 2,958 shares during the period. Nisa Investment Advisors LLC raised its stake in Replimune Group by 10,304.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after buying an additional 4,946 shares during the period. Point72 DIFC Ltd bought a new stake in Replimune Group in the 2nd quarter valued at $57,000. Quest Partners LLC acquired a new stake in shares of Replimune Group during the 4th quarter worth about $76,000. Finally, Diversified Trust Co acquired a new position in shares of Replimune Group in the first quarter valued at approximately $94,000. Institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.